Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration

Biochemical Pharmacology

Volumn 54, Issue 6, 1997, Pages 657-668

  Phillips, J A ^a   Craig, S J ^a   Bayley, D ^a   Christian, R A ^a   Geary, R ^b   Nicklin, P L ^a,c  

^a NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^b ISIS PHARMACEUTICALS   (United States)

^c Novartis Horsham Research Center   (United Kingdom)

Author keywords

Antisense; c raf kinase; ISIS 5132; Oligonucleotide

Indexed keywords

CGP 69846A; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG TISSUE LEVEL; FEMALE; GEL ELECTROPHORESIS; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TISSUE DISTRIBUTION;

ANIMALS; ELECTROPHORESIS, CAPILLARY; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LIVER; MALE; MASS SPECTROMETRY; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RAF; RATS; RATS, WISTAR; THIONUCLEOTIDES; TISSUE DISTRIBUTION; TRITIUM;

EID: 0030776403     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00190-1     Document Type: Article

References (29)

1. Zamecnik PC and Stevenson ML, Inhibition of Rouse sarcoma, virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 75: 280-284, 1978.
2. Helene C and Toulme JJ, Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1049: 99-125, 1990.
3. Crooke ST, Therapeutic applications of oligonucleotides. R. G. Landes Co., Austin, TX, 1995.
4. Higgins KA, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, Rosen CA and Narayanan R, Antisense inhibition of the p65 subunit of NF-KB blocks tumorigenicity and causes tumor regression. Proc Nad Acad Sci USA 90: 9901-9905, 1993.
5. Monia BP, Johnston JF, Geiger T, Mueller M and Fabbro D, Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against c-raf kinase. Nat Med 2: 668-675, 1996.
6. Dean NM, McKay R, Miraglia L, Howard R, Cooper S, Giddings J, Nicklin PL, Miester L, Ziel R, Geiger T, Müller M and Fabbro D, Inhibition of human tumor cell lines in nude mice by an antisense inhibitor of PKC-a expression. Cancer Res 56: 3499-3507, 1996.
7. Agrawal S, Antisense oligonucleotides as antiviral agents. Trends Biotechnol Sci 10: 152-157, 1992.
8. Agrawal S, Temsamani J and Tang JY, Pharmacokinetics, biodistribution and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 88: 7595-7599, 1991.
9. Goodarzi G, Watabe M and Watabe K, Organ distribution and stability of phosphorothioated oligodeoxyribonucleotides in mice. Biopharmacol Drug Dispos 13: 221-227, 1992.
10. Iversen P, In vivo studies with phosphorothioate oligonucleotides: Pharmacokinetics prologue. AntiCancer Drug Design 6: 531-538, 1991.
11. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 267: 1181-1190, 1993.
12. 3H-labeled oligonucleotides. 1. Comparison of a phosphodiester and a phosphorothioate. Mol Pharmacol 45: 932-943, 1994.
13. Agrawal S, Temsamani J, Galbraith W and Tang J, Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 28: 7-16, 1995.
14. Zhang R, Diasio RB, Lu Z, Liu T, Jiang Z, Galbraith WM and Agrawal S, Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM-91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochem Pharmacol 49: 929-939, 1995.
15. Crooke ST, Graham MJ, Zuckerman JE, Brooks D, Conklin BS, Cummins LL, Greig MJ, Kornburst D, Manoharan M, Sasmor H, Schleich T, Tivel KL and Griffey R, Pharmacokinetic properties of several oligonucleotide analogs in mice. J Pharmacol Exp Ther 277: 923-937, 1996.
16. Rifai A, Brysch W, Fadden K, Clark J and Schlingensiepen K-H, Clearance kinetics, biodistribution and organ saturability of phosphorothioate oligodeoxynucleotides in mice. Am J Pathol 149: 717-725, 1996.
17. 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intradermal administration to rats. J Pharmacol Exp Ther 269: 89-94, 1994.
18. Saijo Y, Perlaky L, Wang H and Busch H, Pharmacokinetics, tissue distribution and stability of antisense oligodeoxynucleotide phosophorothioate ISIS 3466 in mice. Oncol Res 6: 243-249, 1994.
19. Leeds JM, Graham MJ, Truong L and Cummins LL, Quantification of phosphorothioate oligonucleotides in human plasma. Anal Biochem 235: 36-43, 1996.
20. Graham MJ, Freier SM, Crooke RM, Ecker DJ, Maslova RN and Lesnik EA, Tritium labeling of antisense oligonucleotides by exchange with tritiated water. Nucleic Acids Res 21: 3737-3743, 1993.
21. Williamson I, Phillips JA and Nicklin PL, Pharmacokinetics, organ distribution and cellular uptake of phosphorothioate oligonucleotides in vivo. Proceedings of the International Conference 'Therapeutic oligonucleotides from Cell to Man', 1995.
22. Crooke RM, In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anticancer Drug Design 6: 609-646, 1991.
23. Beck GF, Irwin WJ, Nicklin PL and Akhtar S, Interactions of phosphodiester and phosphorothioate oligonucleotides with intestinal epithelial cells. Pharmacol Res 13: 1028-1037, 1996.
24. Spitzer S and Eckstein F, Inhibition of deoxyribonucleases by phosphorothioate groups in oligodeoxyribonucleotides. Nucleic Acids Res 16: 11691-11704, 1988.
25. Temsamani J, Tang JY, Padmapriya A, Kubert M and Agrawal S, Pharmacokinetics, biodistribution and stability of capped oligodeoxynucleotide phosphorothioates in mice. Antisense Res Dev 3: 277-284, 1993.
26. Tang JY, Temsamani J and Agrawal S, Self-stabilized antisense oligodeoxynucleotide phosphorothioates: Properties and anti-HIV activity. Nucleic Acids Res 21: 2729-2735, 1993.
27. Zhang R, Lu Z, Zhang X, Zhao H, Diasio RB, Liu T, Jiang Z and Agrawal S, In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats. Clin Chem 41: 836-843, 1995.
28. Galbraith WM, Hobson WC, Giclas PC, Schechter PJ and Agrawal S, Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev 4: 201-206, 1994.
29. Cornish KG, Iversen P, Smith L, Arneson M and Bayever E, Cardiovascular effects of a phosphorothioate oligonucleotide with a sequence antisense to p53 in the conscious rhesus monkey. Pharmacol Commun 3: 239-247, 1993.